The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

HI

Heba Ismail

Principal Investigator

Status: Enrolling By Invitation Ages: 11 Years - 18 Years Gender: All Genders Phase: 2 4 Locations

Brief Description

Obesity prevalence in persons with T1D has increased, which further complicates managementd risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth withbesity as well as potential mechanisms to modify disease.

Detailed Description


Eligibility of study

Inclusion Criteria:
  1. Obese youth 11-18 years of age with T1D at time of enrollment.
  2. Lean youth 11-18 years of age with T1D at time of enrollment.
Exclusion Criteria:
  1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and bygenetic/antibody testing).
  2. History of ongoing infection or antibiotic treatment within the past month;
  3. History of immune-compromise, recurrent infections, steroid intake (inhaled or oral) or other immunosuppressant use in the past 6 months.
  4. History of chronic gastrointestinal disease, possible or confirmed celiac disease;
  5. Participation in any research intervention trials within the past 3 months.
  6. History of treatment or use of metformin, a type 2 diabetes medication.

Interested in participating?

Enrollment in IU School of Medicine clinical trials is managed through our All IN for Health program. Many studies only accept people who are part of an invited group. Visit allinforhealth.info to connect with the study team, or contact your doctor to see if you are eligible.